Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerstin Westermark

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Drug Discovery Today|October 13, 2017
Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in EuropeLaura Fregonese, Lesley Greene, Matthias Hofer, et al.
Orphanet Journal of Rare Diseases|January 28, 2014
Use of biomarkers in the context of orphan medicines designation in the European UnionStelios Tsigkos, Jordi Llinares, Segundo Mariz, et al.
Nature Reviews. Drug Discovery|April 4, 2019
Defining orphan conditions in the context of the European orphan regulation: challenges and evolutionDaniel J O'Connor, Maria E Sheean, Matthias P Hofer, et al.
Nature Reviews. Drug Discovery|May 3, 2011
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Kerstin Westermark, Birthe Byskov Holm, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Drug Discovery Today|October 13, 2017
Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in EuropeLaura Fregonese, Lesley Greene, Matthias Hofer, et al.
Orphanet Journal of Rare Diseases|January 28, 2014
Use of biomarkers in the context of orphan medicines designation in the European UnionStelios Tsigkos, Jordi Llinares, Segundo Mariz, et al.
Nature Reviews. Drug Discovery|April 4, 2019
Defining orphan conditions in the context of the European orphan regulation: challenges and evolutionDaniel J O'Connor, Maria E Sheean, Matthias P Hofer, et al.
Nature Reviews. Drug Discovery|May 3, 2011
European regulation on orphan medicinal products: 10 years of experience and future perspectives, Kerstin Westermark, Birthe Byskov Holm, et al.
Pageof 2